A Randomized Placebo-controlled Crossover Trial Assessing the Efficacy and Safety of M-Gard Particulate EW in the Treatment of Seasonal Allergic Rhinitis
Status: Recruiting
Location: See location...
Intervention Type: Other, Dietary supplement
Study Type: Interventional
Study Phase: Phase 2
SUMMARY
The goal of this clinical trial is to assess the efficacy and safety of M-Gard supplementation for alleviating the symptoms of allergic rhinitis.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 65
Healthy Volunteers: t
View:
• Adults aged 18-65 years.
• Generally healthy
• Individuals with a history of recurrent seasonal allergic rhinitis
• Positive RAST test for grass allergy
• BMI 18-35kg/m2
• Able to provide informed consent
• Agree not to change current diet and/or exercise routine during entire enrolment period
• Agree to not participate in another clinical trial during the study period
Locations
Other Locations
Australia
RDC Clinical
RECRUITING
Brisbane
Contact Information
Primary
Amanda Rao
research@rdcglobal.com.au
+61 (0) 7 3102 4486
Time Frame
Start Date: 2025-06-27
Estimated Completion Date: 2026-01
Participants
Target number of participants: 20
Treatments
Experimental: M-Gard
One capsule containing 250mg of M-Gard Particulate EW is taken twice daily for 14 days.
Placebo_comparator: Placebo
One capsule containing 250mg of MCC (Microcrystalline Cellulose) is taken twice daily for 14 days.
Related Therapeutic Areas
Sponsors
Collaborators: Lallemand Bio-Ingredients
Leads: RDC Clinical Pty Ltd